Newswise — Greetings!

As President of ACTRIMS and Chair of the Steering Committee of the Joint ACTRIMS-ECTRIMS Meeting, it is my great pleasure that I announce the 2014 Joint ACTRIMS-ECTRIMS conference to be held in Boston, Massachusetts (USA), from September 10th to the 13th.

This year’s conference, MSBoston2014, marks the sixth triennial joint conference of ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) and ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis).

We expect this conference to be one of the largest ever, single gatherings of scientists, researchers, clinicians, healthcare professionals, industry and patient advocates dedicated to advancing research and treatment in multiple sclerosis and other demyelinating diseases. In fact, we expect over 6,000 participants from over ninety countries to attend.

This year, we received over 1,700 abstracts. Eleven hundred of them will be presented at the meeting.

I warmly welcome you to join us for this international conference which will have a premiere scientific program that encompasses a breadth of areas in multiple sclerosis including: basic advances, clinical issues, diagnostic strategies, emerging investigational treatments, new treatment strategies, and the latest in repair, remyelination and rehabilitation.

Our interactive and engaging forum will allow for a critical exchange between you and other experts to share findings, discuss progress or insights on effective strategies, and learn about new advances that may help you in your respective field. We are also taking advantage of the social media platform by hosting Burning Debates and Q&A discussions during the meeting which will be live-streamed.

We anticipate many young clinicians and researchers to attend this year’s meeting, which is very exciting. For this triennial, we have awarded 211 Educational Grants to young investigators. And we have two Young Investigators Sessions where select investigators under 35 have been invited to give a platform presentation and share their work. As you are the future of MS research and progress, we value the opportunity to interact with you, and welcome your novel research concepts and ideas.

Finally, we are happy to welcome many pharmaceutical and biotech companies, as well as advocacy and patient groups to MSBoston2014 to contribute to the dialogue and learning about the latest breakthroughs and advances in MS from their own (OR unique) perspectives.

Collectively, we all have a very important role in our mission to address the needs of people living with and impacted by MS. On behalf of ACTRIMS and ECTRIMS, I sincerely thank you for your commitment, and look forward to seeing you in September, in Boston.

I encourage you to register and obtain more information about the meeting, including the scientific program and special events. The meeting website is:

Thank you!Suhayl Dhib-Jalbut